<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003567</url>
  </required_header>
  <id_info>
    <org_study_id>CWRU2Y97</org_study_id>
    <secondary_id>R21CA076192</secondary_id>
    <secondary_id>P30CA043703</secondary_id>
    <secondary_id>CASE-CWRU-2Y97</secondary_id>
    <secondary_id>NCI-T97-0060</secondary_id>
    <secondary_id>CASE-2Y97</secondary_id>
    <nct_id>NCT00003567</nct_id>
  </id_info>
  <brief_title>Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma</brief_title>
  <official_title>Mutant MGMT Gene Transfer Into Human Hematopoietic Progenitors to Protect Hematopoiesis During O6-Benzylguanine (BG, NSC 637037) and Carmustine Followed by Temozolomide Therapy of Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Gene therapy may improve the body's ability to fight cancer or make the cancer&#xD;
      more sensitive to chemotherapy. Drugs used in chemotherapy use different ways to stop tumor&#xD;
      cells from dividing so they stop growing or die.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of gene therapy&#xD;
      together with chemotherapy in treating patients with advanced solid tumors or non-Hodgkin's&#xD;
      lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Evaluate the feasibility of introducing and expressing mutant MGMT-G156A cDNA in&#xD;
           hematopoietic progenitors taken from patients with advanced solid tumors (including&#xD;
           gliomas) or non-Hodgkin's lymphoma using a safety modified retroviral vector MFG.&#xD;
&#xD;
        -  Determine the toxicity associated with reinfusion of ex vivo-transduced hematopoietic&#xD;
           stem cells into these patients, including the detection of replication competent&#xD;
           retrovirus.&#xD;
&#xD;
        -  Evaluate the feasibility of identifying mutant MGMT-G156A-transduced and&#xD;
           O6-benzylguanine (BG)- and temzolomide-resistant hematopoietic and stromal progenitors&#xD;
           from the bone marrow of these patients.&#xD;
&#xD;
        -  Evaluate the feasibility of in vivo enrichment of the transduced hematopoietic&#xD;
           progenitors in patients treated with BG and temzolomide.&#xD;
&#xD;
        -  Evaluate the toxicity of this regimen in these patients.&#xD;
&#xD;
        -  Determine the antitumor effect of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of CD34 stem cells and carmustine.&#xD;
&#xD;
      After a negative bone marrow sampling, patients receive sargramostim (GM-CSF) and filgrastim&#xD;
      (G-CSF) subcutaneously (SC) once daily on days 1-5 (or G-CSF twice daily alone for 4-5 days).&#xD;
      Peripheral blood progenitor cells are collected 24 hours after the last dose of growth factor&#xD;
      injection on day 5 and also on day 6, if necessary. The CD34 positive stem cells are then&#xD;
      infected by the retroviral mutant MGMT-G156A ex vivo.&#xD;
&#xD;
      Patients receive O6-benzylguanine (BG) IV over 1 hour followed by carmustine IV over 1 hour&#xD;
      every 6 weeks for 5 courses, assuming recovery of peripheral blood counts. Approximately 72&#xD;
      hours after the end of the first course of chemotherapy, patients receive reinfusion of&#xD;
      retrovirally-transduced hematopoietic stem cells over 5-10 minutes. Four weeks after the&#xD;
      completion of BG and carmustine, patients receive BG IV over 1 hour followed by temozolomide&#xD;
      IV over 1 hour every 4 weeks for up to 5 courses, in the absence of hematologic toxicity.&#xD;
      Patients with responding disease may continue to receive BG and temzolomide in the absence of&#xD;
      disease progression or unacceptable toxicity provided other phase II studies indicate the&#xD;
      safety of more than 5 courses.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating numbers of CD34 stem cells targeted for retroviral&#xD;
      infection and escalating doses of carmustine.&#xD;
&#xD;
      Patients are followed monthly for 2 months, every 4 months for 8 months, and then every 6&#xD;
      months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 12-18 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    slow accrual&#xD;
  </why_stopped>
  <start_date>May 1999</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gene transfer expression</measure>
    <time_frame>measured at days 28, 56, 84, and 112, and then every 3 months for 1 year</time_frame>
  </primary_outcome>
  <enrollment type="Actual">8</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Lymphoma</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>Patients receive filgrastim (G-CSF) subcutaneously (SC) once daily on days 1-5 (or G-CSF twice daily alone for 4-5 days).</description>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
    <description>Patients receive sargramostim (GM-CSF) subcutaneously (SC) once daily on days 1-5 (or G-CSF twice daily alone for 4-5 days).</description>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic autologous lymphocytes</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>O6-benzylguanine</intervention_name>
    <description>Patients receive O6-benzylguanine (BG) IV over 1 hour every 6 weeks for 5 courses. Four weeks after the completion of BG and carmustine, patients receive BG IV over 1 hour every 4 weeks for up to 5 courses, in the absence of hematologic toxicity. Patients with responding disease may continue to receive BG and temzolomide in the absence of disease progression or unacceptable toxicity.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carmustine</intervention_name>
    <description>Patients receive carmustine IV over 1 hour every 6 weeks for 5 courses.Cohorts of 3-6 patients receive escalating numbers of CD34 stem cells targeted for retroviral infection and escalating doses of carmustine.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
    <description>Four weeks after the completion of BG and carmustine, patients receive temozolomide IV over 1 hour every 4 weeks for up to 5 courses, in the absence of hematologic toxicity. Patients with responding disease may continue to receive BG and temzolomide in the absence of disease progression or unacceptable toxicity.</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>in vitro-treated peripheral blood stem cell transplantation</intervention_name>
    <description>Approximately 72 hours after the end of the first course of chemotherapy, patients receive reinfusion of retrovirally-transduced hematopoietic stem cells over 5-10 minutes. Cohorts of 3-6 patients receive escalating numbers of CD34 stem cells targeted for retroviral infection and escalating doses of carmustine.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  One of the following histologically confirmed diseases for which no curative surgical,&#xD;
             radiotherapy, or chemotherapy programs are available and standard therapy offers, at&#xD;
             best, a modest clinical benefit&#xD;
&#xD;
               -  Solid tumors&#xD;
&#xD;
               -  Gliomas&#xD;
&#xD;
               -  Non-Hodgkin's lymphoma&#xD;
&#xD;
          -  Primary and metastatic CNS malignancies are eligible&#xD;
&#xD;
          -  Evaluable or measurable disease&#xD;
&#xD;
          -  CD34 count at least 2.0 cells/Î¼L&#xD;
&#xD;
          -  No bone marrow involvement&#xD;
&#xD;
               -  Histologically negative bone marrow biopsy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 to 70&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 8.5 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  AST and ALT less than 2.5 times normal&#xD;
&#xD;
          -  Prothrombin time less than 1.2 times normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No acute cardiac disease by EKG&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No symptomatic pulmonary disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No other severe comorbid conditions&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 2 months after study&#xD;
             completion&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  See Chemotherapy&#xD;
&#xD;
          -  No prior hematopoietic stem cell transplantation&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior high-dose chemotherapy&#xD;
&#xD;
          -  Prior adjuvant chemotherapy allowed&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior radiotherapy to 25% or more of bone marrow&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 4 weeks since prior myelosuppressive therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stanton L. Gerson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 9, 2010</last_update_submitted>
  <last_update_submitted_qc>June 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2010</last_update_posted>
  <responsible_party>
    <name_title>Stanton L. Gerson, MD</name_title>
    <organization>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</organization>
  </responsible_party>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>adult brain stem glioma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>adult mixed glioma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult anaplastic oligodendroglioma</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult pilocytic astrocytoma</keyword>
  <keyword>adult subependymoma</keyword>
  <keyword>adult anaplastic ependymoma</keyword>
  <keyword>adult myxopapillary ependymoma</keyword>
  <keyword>adult ependymoblastoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>adult oligodendroglioma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <keyword>adult diffuse astrocytoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>O(6)-benzylguanine</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

